BlueRock expands Toronto ops; Unity brings B round to $151M; Novartis backs Altimmune's $15M raise
⇨ Late last year Bayer and Versant Ventures turned some heads with a $225 million launch for a new stem cell player called BlueRock. Today, the startup announced that it had recruited industry vet Michael Scott as development chief as it created an R&D and manufacturing site in Toronto’s MaRS Discovery District. The biotech is collaborating with the Toronto-based McEwen Centre for Regenerative Medicine at University Health Network.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.